VIDEO: Tralokinumab shows long-term improvement in atopic dermatitis

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-13 blocker tralokinumab from the Maui Derm 2024 meeting, centering around research into longer-term use of the treatment for atopic dermatitis.

Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, highlighted findings that showed high levels of improvement for patients who stayed on the treatment for up to 4 years.

“There was also a really nice bit of real world data that suggested whether somebody has biologic experience or not, in the case of dupilumab, they actually have very similar outcomes overall. So again, giving you a little more flexibility of where tralokinumab might fit in the therapeutic algorithm,” Chovatiya said.